AGADA Biosciences is a privately owned company incorporated in 2013. Our offices and laboratories are located within the state-of-the-art Innovacorp facilities in Halifax, Nova Scotia. The Summer St. labs are shared with Dalhousie University, and the new murine facilities are maintained by expert Dalhousie University staff.

AGADA’s mission is to meet the rapidly growing need for services that accelerate drug development for orphan diseases, with specific expertise in models of Duchenne muscular dystrophy and other neuromuscular diseases.

AGADA facilitates orphan drug development for industry, non-profits, and academic-based groups. Services offered by AGADA include pre-clinical testing and research in models (in vivo efficacy), cell-based assays (in vitro), and surrogate biomarker discovery and applications. Drs. Nagaraju and Hoffman, the co-founders of AGADA, are key opinion leaders for pre-clinical efficacy studies and have helped lead international efforts to develop standard operating procedures (SOPs) for pre-clinical outcome measures in muscular dystrophy models with the trans-EU, TREAT-NMD group. For your human trials, we provide advice on human trial design, regulatory writing, biomarker method development, qualification, and validation.  We ensure that the muscle biopsies in your trials yield robust results.

Drs. Nagaraju and Hoffman hold Adjunct Faculty appointments in the Department of Pharmacology at Dalhousie University.